scispace - formally typeset
R

Robert Fagard

Researcher at Katholieke Universiteit Leuven

Publications -  788
Citations -  109235

Robert Fagard is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Blood pressure & Ambulatory blood pressure. The author has an hindex of 114, co-authored 787 publications receiving 104613 citations.

Papers
More filters
Journal ArticleDOI

Systolic Hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol, and initial progress. Systolic Hypertension in Europe Investigators

TL;DR: This open follow-up study aims to confirm the safety of long-term antihypertensive therapy based on a dihydropyridine and to lower the sitting systolic bp below 150 mm hg (target bp), the first-line agent nitrendipine may be associated with enalapril and other study drugs.
Journal ArticleDOI

Response of the systemic and pulmonary circulation to alpha- and beta-receptor blockade (labetalol) at rest and during exercise in hypertensive patients.

TL;DR: Hemodynamic observations suggest that the antihypertensive action of L is based mainly on its f-receptor blocking properties at RR, and on both its aand f- receptor blocking effects sitting and at exercise.
Journal ArticleDOI

Comparison of cardiac output measured by two automated methods of CO2 rebreathing

TL;DR: The reproducibility of the exponential method of CO2 rebreathing with the use of automated curve fitting was investigated and whether this method is superior to the equilibrium method in terms of reproducecibility and clinical practicability was determined.
Journal ArticleDOI

Relationship between left ventricular mass and the ACE D/I polymorphism varies according to sodium intake

TL;DR: The relationship between LVMI and the ACE D/I polymorphism differs across populations, possibly as a consequence of intermediate regulatory mechanisms responsive to varying levels of salt intake.
Journal Article

Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial

TL;DR: It is shown that significant BP reduction can be achieved and maintained in older Chinese patients treated with a calcium antagonist associated with a converting-enzyme inhibitor and a thiazide, as necessary, up to 3 years of follow-up.